1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Taking It To The Front Lines: PD-1 Inhibitors Moving Earlier In Lung Cancer

 
• By Emily Hayes

With data on Merck’s pembrolizumab and Bristol’s nivolumab in lung cancer, the question has become whether the response rates are good enough to consider first-line therapy. It is also becoming a proving ground for PD-L1 expression as a biomarker for the class.

Data for competing anti-PD-1 antibodies from Merck & Co. Inc. and Bristol-Myers Squibb Co. in first-line lung cancer raised questions at the recent American Society of Clinical Oncology annual meeting about how good response rates need to be in this important indication and whether PD-L1 is the right biomarker to select patients.

Lung cancer is one of many indications where PD-1 and PD-L1 inhibitors could play a role (see related story, [A#00140609014]). Due to the large patient population, it’s been a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

More from R&D

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Pink Sheet Podcast: US FDA’s Big Vaccine Policy Week

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.